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Giant cell tumor of the bone (GCTB) is a benign, locally aggressive 
neoplasm that is relatively rare, with a propensity to result in progressive 
bone destruction, and is associated with a high risk of recurrence. There is 
no widely held consensus regarding its ideal treatment. Worldwide, there 
are varying techniques ranging from intralesional curettage to resection 
of the lesion, supplemented with combinations of numerous adjuncts and 
fillers, depending on the resected amount and integrity of bone, as well as 
the preference of the surgeon.
This was a cross-sectional study that included 20 patients who underwent 
limb salvage surgery for giant cell tumor of the bone of the lower 
extremities from January 2009 to February 2020 at two tertiary hospitals.
The mean follow-up period was 37.3 months (SD=2.84). The extended 
curettage (EC) group had a mean Musculoskeletal Tumor Rating Scale 
(MSTS) score of 28.18 (SD=7.51) which is considered as an excellent 
outcome, while the resection (RS) group had an mean MSTS score of 
19.67 (SD=11.02), which is considered as a good outcome. EC resulted 
to a total of eight complications (47%), while RS had one complication 
(33%). Prevalence of recurrence was noted to be 11.75% among those 
who underwent EC, while no recurrence was noted among those in the RS 
group. Use of bone cement as a filler was noted to have less recurrence as 
compared with the use of bone grafts, however were both were noted to 
result in excellent functional outcomes.
Despite the prevalence of complications and recurrence of GCTB of the 
salvaged extremity in those who underwent EC, there is still report of 
excellent functionality. It is hence important to disclose all these possible 
outcomes and to stress the importance of compliance to follow-up for 







Giant cell tumor of the bone (GCTB) is a benign but 
locally aggressive neoplasm comprising approximately 5% 
of all primary bone tumors [1-6,9,15,16,18,20]. The natural his-
tory of GCTB is progressive bone destruction leading to 
joint deformity and disability, and despite it rarely causing 
death, it displays a tendency for local recurrence occur-
ring within two years of the index surgery, and pulmonary 
metastasis (1.8-9.1% of cases) has also been described 
[1,2,5,6,14,15,21]. There are documented cases of malignant 
transformation in less than 1% of GCTs and are hence 
considered rare [1,5,6].
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There is no widely held consensus regarding the ideal 
treatment method selection of GCTBs. Options of chemo-
therapy and radiotherapy are reserved for select cases 
however evidence shows no clear benefit for its use in 
these cases [2,14]. Treatment has become mainly surgical 
and is the universal standard of care due to the association 
of GTCB with substantial disturbance of local bony ar-
chitecture especially in periarticular locations [2,4-6,14,15]. In 
our institution, as well as worldwide, there are advocates 
of varying surgical techniques ranging from intralesional 
curettage to wide excision of the lesion, supplemented 
with cement augmentation and fixation with implants, 
depending on the amount of bone resected, integrity of the 
articular surface, and the preference of the surgeon [2].
Regardless of technique, the goal of limb-salvage are 
eradication of the tumor, preservation of limb function, 
and prevention of local recurrence and distant metastasis 
[2,5,14], as some studies show a correlation of the rate of 
local recurrence varying with the extent of GCT removal 
[2,3,6,22]. Patients with wide resection of the tumor are noted 
to have a local recurrence rate approaching 0% [6], but with 
these leading to higher rates of surgical complications and 
may lead to functional impairment, necessitating recon-
struction [2,3,18]. On the other hand, intralesional curettage 
despite resulting in less morbidity and functional impair-
ment, regardless of how thoroughly performed, leaves 
microscopic disease and hence has a reported recurrence 
rate as high as 60-65% [2,3,14,18,20]. This has led surgeons 
to enhance surgical procedures with the use of adjuvants 
such as liquid nitrogen, cement, phenol, hydrogen per-
oxide, which in some studies, have shown to be useful in 
decreasing recurrence rates [2,4].
In the Philippines, options for limb-salvage surgery for 
malignant and aggressive extremity neoplasms after tumor 
excision are limited as they would often entail the use of 
bone grafts, not only due to the sheer size of the defects 
left in the aftermath of the procedure, but also due to the 
unavailability and unaffordability of tumor prosthesis and 
implants [4], often resulting to amputation of the involved 
extremity. In this developing country, there are only a few 
centers with an active bone bank, and our institution is 
honored to house one of them, for which a stock of allo-
grafts are available for use intraoperatively. 
To date, possibly owing to the relative rarity of the 
disease, there has been no other published work in re-
gards to the functional outcomes of patients in the Phil-
ippines diagnosed specifically with GCTBs of the lower 
extremity who underwent limb-salvage surgery, as well 
as the complication and recurrence rates following the 
aforementioned procedure. The researchers would like to 
provide evidence for this gap in knowledge, as well as to 
determine the outcomes of the usage of allografts in this 
population who have access and are able to afford this 
modality.
2. Materials and Methods
Study Design and Procedure
This was a cross-sectional study investigating patients 
who underwent limb-salvage surgery of the lower ex-
tremity for GCTB from January 2009 to February 2020 at 
two tertiary hospitals. Limb salvage surgery in this study 
is defined as resection (RS) or extended curettage (EC) 
of the GCTB lesion of a Campanacci grading of II or III, 
with or without the use of local adjuvants, with the goal of 
eradication of the tumor, preservation of the limb and its 
function, and prevention of recurrence.
Due to the relative rarity of the disease, convenience 
sampling of the cases of interest was done. A thorough re-
view of the patient’s electronic hospital records (Enterprise 
Portal v1.6.1 rev.219), including the operative record for 
details regarding the surgery was done. All information 
was collated using a data collection tool.
Functional outcomes, on the other hand, were derived 
from the surgeon’s clinic charts of the patient’s subsequent 
follow-up visits postoperatively. These were rated using 
the Musculoskeletal Tumor Rating Scale (MSTS), a vali-
dated questionnaire developed initially by Enneking et al 
in 1993 and has been in use for over 20 years as a widely 
recognized tool to evaluate function. This system meas-
ures outcomes in seven categories, including motion, pain, 
stability, deformity, strength, activity, and emotional ac-
ceptance, specified to the anatomic location of interest (ie, 
hip, knee, or ankle) [8]. Each parameter is scored 0-5 and 
combined for a possible total score of 35. A score of 23 or 
greater is considered an excellent result; a score of 15-22 
is considered a good result; a score of 8-14 is considered a 
fair result; and lastly, a score of less than 8 is considered a 
poor result, in terms of functionality [9]. 
Likewise, the occurrence of any complication or re-
currence was noted using these records. The development 
of progressive lucency at the cement-bone interface in 
radiographs, or the presence of osteolysis and presence of 
a soft tissue mass in CT or MR imaging following surgery 
suggests recurrence of GCTB [6]. A complication on the 
other hand is defined as any event for which the patient 
required a specific intervention such as wound complica-
tions, infection, implant failure/loosening, fracture, and 
stiffness of the joint [4].
Approval was first obtained from the Institutional Re-
view Board and Ethics Committee of our institution prior 
to the commencement of this study. 
DOI: https://doi.org/10.30564/jor.v3i2.3669
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Eligibility Criteria
Inclusion criteria for the patients to be recruited were 
as follows:
(1) More than 18 years old during time of the diagnosis 
of GCTB and of limb-salvage surgery;
(2) Diagnosed with GCTB of the lower extremity via 
imaging (radiographs, CT scan, MRI);
(3) Classified with GCTB Campanacci grade II or III 
who underwent limb-salvage surgery, at either St. Luke’s 
Medical Center-Quezon City or Bonifacio Global City;
(4) Has a histopathology result confirming the diagno-
sis of GCTB;
(5) With active follow-up of up to at least 6 months 
post-operatively;
Exclusion criteria are as follows:
(1) Those with open wounds, skin lesions directly 
overlying the surgical area, and/or active infections (either 
local or systemic);
(2) With pre-surgical conditions or comorbidities other 
than GCTB rendering the patient unable to ambulate or do 
range of motion of the lower extremities;
(3) With incomplete medical data from either hospital 
or clinic records;
Study Procedures
Due to the relative rarity of the disease, convenience 
sampling of the cases of interest was done. After these 
select cases were listed, identification of the attending sur-
geons was done, each of which were individually contact-
ed to inform them of the eligibility of their patient/s.
After their confirmation, a thorough review of the pa-
tient’s database and electronic hospital records (Enterprise 
Portal v1.6.1 rev.219) during his/her admission, including 
the operative record for details surrounding the surgery 
will also be done. Follow-up data, on the other hand, were 
obtained from the surgeon’s clinic charts of the patient’s 
subsequent visits postoperatively to determine information 
on his/her functional outcomes, which were completed by 
the investigator using the MSTS questionnaire. All infor-
mation obtained will be collated using a data collection 
tool. 
Objectives
The general objective of this study aimed to determine 
the outcomes of limb-salvage surgery in patients diag-
nosed with GCTB of the lower extremities. The specific 
objectives were to obtain the following:
Demographic and surgical profile of the selected partic-
ipants.
Functional outcomes among participants using the 
Musculoskeletal Tumor Rating Scale (MSTS) score in 
terms of their motion, pain, stability, deformity, strength, 
activity, and emotional acceptance. This will be deter-
mined according to surgical techniques as well as accord-
ing to the use of fillers. Each parameter is scored 0-5 and 
combined for a possible total score of 35. A score of 23 or 
greater is considered an excellent result; a score of 15-22 
is considered a good result; a score of 8-14 is considered a 
fair result; and lastly, a score of less than 8 is considered a 
poor result, in terms of functionality [9].
Recurrence and complications among the participants. 
This will also be determined according to surgical tech-
niques and use of fillers. The development of progressive 
lucency at the cement-bone interface in radiographs, or 
the presence of osteolysis and presence of a soft tissue 
mass in CT or MR imaging following surgery suggests 
recurrence of GCTB [6]. A complication on the other hand 
is defined as any event for which the patient required a 
specific intervention such as wound complications, infec-
tion, implant failure/loosening, fracture, and stiffness of 
the joint [4].
Sample size estimation
Sample size was calculated based on the estimation of 
the population proportion for functional score (MSTS). As 
suming that the proportion of post-limb salvage surgery 
in patients with primary bone tumors with good to excellent 
results is 90% [9], with a maximum allowable error of 7.5%, 
and a reliability of 80%, the sample size required is 27.
Statistical Analysis
Statistical analyses were performed using STATA Sta-
tistical Software, Version 13, College Station, TX; Stat-
aCorp LP. Descriptive statistics involved mean, standard 
deviation, frequency, percentage, median, and interquar-
tile range. Descriptive statistics on the functional out-
comes, and complication occurrence and recurrence was 
estimated using chi-square test exact binomial with a 95% 
confidence interval (95% CI). All valid data were included 
in the analysis. Missing variables was neither imputed nor 
estimated. 
3. Results
We analyzed a total of 20 patients diagnosed radio-
graphically and histologically with giant cell tumor of the 
bone of the lower extremities that underwent limb salvage 
surgery in our institution from January 2009 to February 
2020. Table 1 illustrates the demographic and surgical 
profiles of the respondents. It can be noted that the mean 
age of the respondents was 31.70 years (SD=9.44). Ma-
DOI: https://doi.org/10.30564/jor.v3i2.3669
63
Journal of Oncology Research | Volume 03 | Issue 02 | July 2021
Distributed under creative commons license 4.0
jority of the respondents were males (55%), had femoral 
distal third involvement (40%), and had a Campanacci 
score of III (55%). There is a mean tumor size of 4.12 
cm (SD=2.20) anteroposteriorly, 4.92 cm (SD=2.78) 
craniocaudally, and 4.92 cm (SD=2.73) transversely. 
Majority of the respondents underwent EC (85%) along 
with electrocautery with hydrogen peroxide (20%). The 
most commonly used filler was bone cement (35.29%). 
The mean operative time was 4.68 hours (SD=1.87), with 
a mean intraoperative blood loss of 549.00 milliliters 
(SD=764.97). The mean duration of hospital stay was 
5.25 days (SD=2.84). There was note of shorter duration 
of operative time (EC 4.28 hrs vs RS 6.94 hrs), less intra-
operative blood loss (EC 351.76 mL vs RS 1,666.67 mL), 
and shorter hospital stay (EC 4.53 days vs RS 9.33 days), 
in favor of the EC group. The duration of follow-up visit 
ranged from 6 months to 8 years, with a mean of 37.30 
months (SD=30.64). It was also observed that among all 
the respondents, only 25% (5/20) of the respondents had 
used denosumab.
Table 2 illustrates the descriptive statistics of the MSTS 
score according to surgical techniques. It is noted that 
Table 1. Demographic and Surgical Profiles of the Respondents (N = 20)
Characteristics Frequency (f) Percentage (%) Mean (SD)









Tibia – Proximal Third 7 35.00%
Tibia – Distal Third 1 5.00%
Femur – Proximal Third 3 15.00%

















Electrocautery with Phenol 2 10.00%
Electrocautery with Burr 2 10.00%
Electrocautery with Burr and Phenol 2 10.00%
Electrocautery with Hydrogen Peroxide 4 20.00%
Electrocautery with Burr and Hydrogen Peroxide 3 15.00%
Electrocautery with Hydrogen Peroxide and Ethanol 2 10.00%
Use of Fillers
Bone Cement 6 35.29%
Femoral Head Allograft alone 1 5.88%
Hydroxyapatite Crystals alone 3 17.65%
Femoral Head Allograft with Autograft 3 17.65%
Femoral Head Allograft with Bone Cement 3 17.65%
Femoral Head Allograft with Bone Cement and DBM 1 5.88%






Duration of Operation Time (Hours) 4.68 (1.87)
Resection 6.94 (1.42)
Extended Curettage 4.28 (1.67)






Duration of Follow-up (Months) 37.30 (30.64)
DOI: https://doi.org/10.30564/jor.v3i2.3669
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among the different variants of EC, the use of electrocau-
tery with phenol produced the highest MSTS score of 34 
(SD=1.41). Overall, the approaches of EC had a mean 
score of 28.18 (SD=7.51) which is considered generally as 
an excellent outcome, while RS had a mean score of 19.67 
(SD=11.02), which is generally considered as a good out-
come.
The descriptive statistics of the MSTS score according 
to the use of fillers are presented in Table 3. It is noted 
that the use of femoral head allografts in general resulted 
in excellent outcomes (mean 24.37, SD=9.10), similar to 
the use of bone cement (mean 31.33, SD=5.12), and hy-
droxyapatite crystals (mean 31.00, SD=2.00).
Table 4 shows the descriptive statistics for the preva-
lence of complications and recurrence according to sur-
gical technique. As demonstrated, among 17 cases of EC, 
there was a total of 8 complications (47%), including con-
tractures (2), implant irritation (2), osteoarthritic changes 
(2), iatrogenic fracture (1), and arthrofibrosis (1). Among 
the three cases of RS, on the other hand, only 1 complica-
tion of postoperative infection (33%) was noted. Recur-
rence overall was 2 out 20 cases (10%) but segregated to 
technique, it was not noted in the resection group, while 
both cases were from the EC group (11.76% [2/17]).
The descriptive statistics of the prevalence of com-
plications and recurrence according to the use of fillers 
are presented in Table 5. Five patients among those who 
utilized femoral head grafts (62.5%) as fillers were noted 
to develop complications (3/5 developed more than one 
complication). Likewise, both recurrences noted in this 
study both had use of femoral head allografts (25%).
4. Discussion
GCTB accounts for only 5% of all primary bone tu-
mors [1-6,9,15,16,18,20] and are known to be locally aggressive 
benign tumors, and a propensity to be highly recurrent 
but with a rare metastatic potential [1,5,6,14,15]. Most of these 
lesions develop in long bones (75%-90%), with majority 
of cases (50-65%) occurring adjacent to the knee [2,5,6,9,16,18]. 
This was similar to our study, which showed the most 
commonly affected sites being the distal femur (40%) 
and proximal tibia (35%). Due to its common affliction in 
these areas, the natural history of GCTB leads to morbid-
ity resulting from the substantial disturbance of the local 
bony architecture of these periarticular locations [2,3,9,21]. 
Although some studies show an equal sex distribution, 
most show a slight predilection among females [2,3,5,6,15,22]. 
This was in contrast to our study, as it was noted that the 
majority of our population (55%) comprised of males. 
Multiple studies have likewise shown that GCTB may oc-
cur in any age group but is observed to peak during the 3rd 
decade, with 80% of cases occurring between 20-50 years 
of age [3,5,6,15,20,22]. This is in concordance with our study, 
showing a mean age of 31.70 years. 
The high suspicion for a diagnosis of GCTB begins 
with a typical radiographic presentation of a lytic bony 
Table 2. Descriptive Statistics of Musculoskeletal Tumor Rating Scale (MSTS) according to Surgical Technique among 







































31.00 (0.00) 34.00 (1.41) 25.00 (11.31) 27.00 (8.49) 29.00 (5.66) 27.33 (11.59) 23.50 (13.44)
Values are presented as mean 
(standard deviation). 
Table 3. Descriptive Statistics of Musculoskeletal Tumor Rating Scale (MSTS) according to Use of Fillers among the 






















Femoral head allograft 
with bone cement and 
demineralized bone 
matrix (N=1)
Overall Score 31.33 (5.12) 31.00 (2.00) 24.37 (9.10) 35.00 (0.00) 17.00 (3.60) 26.67 (10.97) 29.00 (0.00)
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lesion that is well-defined and with non-sclerotic margin 
and an eccentric, mostly epiphyseal location, extending to 
the subchondral bone, but may often times present with 
more aggressive features, ranging from a wide zone of 
transition with cortical thinning and expansile remodeling 
to cortical bone destruction [1,3,6,16]. The Campanacci grad-
ing was created to classify GCTB based on their radio-
graphic appearance and has been proposed to guide treat-
ment [3,5]. Type I are considered latent and are represented 
by small lesions which are well-defined and with an intact 
cortex, for which there is more room for conservative 
management. Type II (Figure 1A) are considered active 
and relatively well-defined, described as typically larger 
than type I lesions but with an intact periosteum. Type III 
(Figure 2A) are aggressive lesions, with indistinct borders, 
extending through the periosteum and surrounding tissues 
[3]. In our study, 45% of the respondents had grade II and 
55% had grade III GCTB lesions. It has been suggested 
that grade II lesions should be treated with intralesional 
curettage and grade III lesions with resection and recon-
struction [5]. However, this recommendation has not been 
incorporated into guidelines, as there is lack of correlation 
between the grade and the aggressiveness of the GCT and 
does not provide reliable prognostic significance in terms 
of recurrence and functional outcomes [5,20]. Further, a 
study done by Omlor et al last 2019 likewise shows that 
Table 4. Descriptive Statistics of the Prevalence of Complications and Recurrence among the Respondents according to 






























1.00 (50.00%) 1.00 (50.00%) 0.00 (0.00%) 0.00 (0.00%) 0.00 (0.00%)
Implant Irritation 0.00 (0.00%)
2.00 
(11.76%)




























0.00 (0.00%) 0.00 (0.00%) 1.00 (25.00%) 0.00 (0.00%) 1.00 (50.00%)
Values are presented as frequency 
(percentage).
Table 5. Descriptive Statistics of the Prevalence of Complications and Recurrence among the Respondents according to 









allograft with bone 
cement (N=3)
Femoral head allograft 
with autograft (N=3)
Femoral head allograft with 
bone cement and demineralized 
bone matrix (N=1)
Contractures 1.00 (12.50%) 1.00 (12.50%) 1.00 (33.30%) 0.00 (0.00%) 0.00 (0.00%)
Implant Irritation 0.00 (0.00%) 2.00 (25.00%) 1.00 (33.30%) 1.00 (33.30%) 0.00 (0.00%)
Osteoarthritic 
Changes 
0.00 (0.00%) 2.00 (25.00%) 1.00 (33.30%) 1.00 (33.30%) 0.00 (0.00%)
Infection 0.00 (0.00%) 0.00 (0.00%) 0.00 (0.00%) 0.00 (0.00%) 0.00 (0.00%)
Iatrogenic 
Fracture
0.00 (0.00%) 1.00 (12.50%) 1.00 (33.30%) 0.00 (0.00%) 0.00 (0.00%)
Athrofibrosis 0.00 (0.00%) 1.00 (12.50%) 1.00 (33.30%) 0.00 (0.00%) 0.00 (0.00%)
Recurrence
(N=2)
0.00 (0.00%) 2.00 (25%) 0.00 (0.00%) 1.00 (33.33%) 1.00 (100.00%)
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Campanacci grade, as well as soft tissue infiltration, and 
larger size of the lesion does not significantly impact the 
recurrence of GCTB [15].
Figure 1. This demonstrates a case done under extended 
curettage. Preoperative radiographs (A) and MRI (B) re-
veal a Campanacci II GCTB of the proximal tibia and pa-
tient underwent surgery. Surgical markings (C) were done 
to map the landmarks, area of the lesion, and the planned 
incision. Curettage (D) was performed revealing grayish, 
friable tissue. Extended curettage followed using ethanol 
(E), hydrogen peroxide (F), electrocautery (G), and use 
of a highspeed burr (H). Bone grafting (I) was done using 
autologous iliac bone graft adjacent to the articular surface 
and morselized femoral head allograft to fill the rest of the 
defect. Postoperative radiographs (J) show placement of a 
4-hole L-plate to the medial aspect of the proximal tibia, 
augmenting the construct.
Due to the wide range of differential diagnoses that 
can mimic GCTB in imaging, the diagnosis is ascertained 
only after a biopsy is obtained. The protocol and goal of 
the biopsy follows as in any other bone tumor. Only upon 
histopathologic reading of GCTB has been confirmed may 
surgical planning and treatment proceed [2,3,5]. Surgery is 
the standard treatment for GCTB, and depending on the 
involvement of the articulating surfaces, the tumor can be 
removed either by resection or curettage, with or without 
adjuvants [2,4-6,14,15] There is still controversy about the 
surgical management of choice, however the therapeutic 
goals of surgery remains the same: to achieve a balance 
between maximizing the removal of the tumor while re-
ducing recurrence rate, preserving function, and prevent-
ing occurrence of complications [9,15]. 
Curettage alone has been the opted treatment of GCTB, 
due to its ability to provide less morbidity and functional 
impairment, but regardless how thoroughly curettage is 
performed, it is associated with local recurrence rates as 
high as 65% [5,15]. Wide resection (Figure 3), on the other 
hand, is associated with decreased risk of local recurrence 
approaching 0% compared to intralesional curettage [2,19]. 
Despite this however, it is associated with greater surgi-
cal morbidity and disability problems leading to poorer 
functional outcomes [3,14,22]. A retrospective cohort study 
done by Jamshidi et al investigating the outcomes of pa-
tients with Campanacci grade III GCTB of the knee who 
underwent either RS or EC showed that function was sig-
nificantly better in the EC group in comparison to the RS 
counterpart [18]. This further supports the findings in our 
study, showing good outcomes in those that underwent RS 
(MSTS 19.67, SD=11.02) in contrast to those that under-
went EC who had excellent outcomes (MSTS score 28.18, 
SD=7.51). Some studies attribute this to curettage being 
less invasive as well as being able to preserve the joint 
adjacent to the tumor [15,20]. In contrast, resection results 
in gradual development of mechanical and structural dif-
ficulties in the prostheses of the knee joint, thus affecting 
the outcomes of these patients in the long term [9,10,14,18,20]. 
A long-term study by Houdek et al investigating the ef-
fects of prosthesis on periarticular tumors of the distal 
femur reports the same findings and found a high risk of 
revision and reoperation [11]. This was likewise reported 
in the study of Jamishidi that showed significantly more 
revision surgeries in those that underwent RS [18].
Further, evidence shows that 97% of recurrences will 
occur within two years, with a recurrence after three years 
being considered exceptional [2,3,14]. As mentioned, high 
local recurrence rate in curettage without local adjuncts was 
already described in previous studies [5,15,19]. Hence, EC (Fig-
ure 1 and 2) or the addition of local adjuvants such as cryoabla-
tion with liquid nitrogen, alcohol, phenol, ethanol (Figure 1E), 
zolendronic acid, hydrogen peroxide (Figure 1F), electrocautery 
(Figure 1G), speed burr drilling (Figure 1H), and bone ce-
ment (Figure 2H) and combinations of these in addition to 
curettage to eradicate additional tumor cells has shown to de-
crease the recurrence in general to 6-25% [3-6]. This is in con-
cordance with our study, with a recurrence of 11.76% (2/17) 
among those who underwent EC.
DOI: https://doi.org/10.30564/jor.v3i2.3669
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Figure 2. This demonstrates another case utilizing a 
different technique of extended curettage. Preoperative 
radiographs (A), MRI (B), and CT scan (C) reveal now a 
Campanacci III GCTB proximal tibia and patient under-
went surgery. Surgical markings (D) were likewise done. 
Complete exposure (E), and extended curettage proceeded 
with the use of adjuvants including hydrogen peroxide 
and electrocautery in 3 cycles. Two femoral heads were 
secured. One was prepared by removal all surrounding 
cortical bone and cartilage using a saw to shape it ac-
cording to the subchondral defect adjacent to the articular 
surface (G). Plating was then done and patellar tendon 
was reconstructed and anchored to a post and washer 
screwed into the tibial shaft; bone cement was then added 
to augment the fixation (H). Postoperative radiographs (I) 
show the final construct.
Figure 3. This demonstrates a resection case. Preopera-
tive radiographs (A) and MRI (B) reveal a Campanacci III 
GCTB of the distal femur and patient underwent surgery. 
Surgical markings (C) were done to map the landmarks, 
area of the lesion, and the planned incision. Complete 
exposure (D) and distal femoral resection were done, 
revealing a mass measuring 11x10x10cm. Measurements 
of the femoral shaft and tibial plateau were done and bone 
cement spacer was shaped accordingly and attached to the 
end of an intramedullary nail (F). Nail was then secured 
in place to the femur using a 26mm proximal screw (G). 
Postoperative radiographs (H) show the implant in place.
In our study, the most common local adjuvant used to 
extend curettage was hydrogen peroxide alone, compris-
ing 20% of the adjuvants used, and has been as well used 
in combination with burr and ethanol in 15% and 10% of 
cases respectively. This may be due to hydrogen peroxide 
being cheap and easily available, at the same time, being 
reported as an alternative for phenol with proven in vitro 
effects against GCT cells [15]. It is noteworthy, however, 
that hydrogen peroxide use was also seen in the two doc-
umented recurrences in our study. Hydrogen peroxide, as 
demonstrated by Omlor et al, works by inducing apoptosis 
of cells, and although it has demonstrated a significantly 
reduced recurrence rate versus in those not treated with 
hydrogen peroxide and increased recurrence-free survival 
rate, recurrence can still occur in as high as 22% [15]. In 
the same study, it was also demonstrated that hydrogen 
peroxide use versus no hydrogen peroxide use did not sig-
nificantly influence functional outcomes.
Likewise, electrocautery was also a commonly used 
local adjuvant and was noted to be used in combination 
in all 20 cases in our study, but used alone in only 10%. 
A study investigating the isolated use of electrocautery as 
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a local adjuvant for benign bone tumors showed a recur-
rence of 20.8% in giant cell tumors [17].
Other local adjuvants used in this study were phenol, 
ethanol, and burr. Phenol, although is considered histori-
cally as the most prevalent chemical adjunct in the treat-
ment of GCTB for its ability to cause cell lysis and death 
and is able to decrease recurrence rate to 6-18%, was 
found to cause serious chemical burns and can be sys-
temically toxic, hence have not been as commonly used 
[19,21]. Ethanol, on the other hand, is more readily available 
and less toxic as well [21]. A study by Jones et al reports 
a recurrence rate of 13.5% following primary curettage 
of GCTB with adjuvant ethanol [21]. Some authors would 
recommend the use of a burr to help break ridges of bone 
in order to obtain adequate exposure of the lesion during 
curettage and improve the thoroughness of tumor removal 
[14,16]. A study by Balke et al in 2007 mentions that the use 
of a high-speed burr decreases residual tumor cells in the 
area by its thermal effect and the likelihood of recurrence 
was 4 times higher if burring was not done [19]. Despite 
this, there are reports of a 12% recurrence rate with the 
use of burrs in combination with EC [2,3].
As these multiple studies portray, these adjuncts tested 
alone and in combination were proven to reduce the rate 
of local recurrence, however there always seems to be a 
risk of recurrence that may be attributed to residual micro-
scopic disease often under pockets or ridges of bone [3,19]. 
In addition, due to their heterogenous use, their effective-
nesss in terms of reducing recurrence has not been proven 
[15,19]. Hence, recurrence still has to be discussed with pa-
tients as possible outcomes of surgery.
In this paper, there were eight cases that utilized fem-
oral head allograft as fillers in defects after curettage was 
performed. These grafts offer advantages such that it 
undergoes remodeling and once incorporated, may offer 
permanent stock and support in a defect [14]. Among these 
eight cases, the two documented recurrences both had use 
of these allografts. A study by Sobti et al notes that bone 
graft reconstruction in addition to curettage alone is only 
able to afford some local control and may have recurrence 
rates as high as 50%, and hence is recommended to be 
used in adjunct to other forms of EC [3]. However, to pre-
vent cartilage destruction, adjuvants to EC such as burring 
and electrocautery may not be done as aggressively as 
needed thereby explaining why recurrence might be high-
er in these cases [19]. 
On the other hand, the use of polymethylmethacrylate 
(PMMA) alone was the most common filler used for de-
fects in this study, comprising 35.29%. The advantages of 
this alternative include its availability, cost, and can offer 
immediate stability for patients where compliance is of 
question [16]. It has also been reported that use of PMMA 
results in local hyperthermia which may induce necrosis 
of residual disease of up to 3 mm, decreasing recurrence 
to 10-14% [2,3]. The downside to using bone cement in 
subchondral regions is that it may damage the adjacent 
articular cartilage.
A study done by Gao et al investigated functional out-
comes in patients treated with bone grafts versus bone 
cement following curettage in patients with GCT of the 
long bones. Their study found that MSTS scores were 
significantly lower than in patients treated with bone graft 
compared with bone cement. which was contrary to the 
findings in our study, which reported excellent outcomes 
for both bone cement and bone allografts. Their study 
also reported a higher recurrence rate in patients treated 
with bone grafting. The same findings were found in our 
study and a study done by Vaishya et al likewise found 
that recurrence rate was significantly higher in patients 
treated with bone grafting as compared with patients with 
PMMA [22]. However, it was recommended that ultimately, 
extensive curettage be performed extensively with some 
adjuvant therapy to help in decreasing the incidence of 
recurrence [22]. In addition, as mentioned in the study of 
Klenke et al, the selection of bone graft versus cement 
should always remain individualized [16].
5. Conclusions
There is excellent functional outcome among patients 
who underwent EC as compared to those who underwent 
RS as limb salvage surgery for GCTB of the lower ex-
tremity. However, there was also note of higher incidence 
of complications in those who underwent EC over RS. 
This may indicate that despite the occurrence of compli-
cations of the salvaged extremity, this does not necessarily 
associate with poor outcomes as the patients continue to 
report good functionality. Nevertheless, it is important 
to keep in mind that in the face of excellent outcomes, 
there is still the possibility of recurrence that is associated 
with EC. Surgeons must hence reiterate the importance of 
compliance to follow-up to monitor subsequent events. It 
is recommended that a larger population and a longer fol-
low-up be used in future studies to increase the power and 
generalizability of the results of this study.
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